<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808362</url>
  </required_header>
  <id_info>
    <org_study_id>OMO-103-01</org_study_id>
    <nct_id>NCT04808362</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours</brief_title>
  <acronym>MYCure</acronym>
  <official_title>A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumour Activity of the MYC Inhibitor OMO-103 Administered Intravenously in Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peptomyc S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peptomyc S.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open label, two-part, First in Human (FIH) Phase 1/2 dose-finding study&#xD;
      designed to determine the safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD)&#xD;
      and proof-of-concept (POC) of OMO-103 in patients with advanced solid tumours.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open label, two-part, FIH Phase 1/2 dose-finding study designed to determine&#xD;
      the safety, tolerability, PK, PD and proof-of-concept of OMO-103 in patients with advanced&#xD;
      solid tumours.&#xD;
&#xD;
      The study consists of two parts:&#xD;
&#xD;
      • Part 1: Dose escalation in patients with advanced solid tumours, including 5 OMO-103 dose&#xD;
      levels.&#xD;
&#xD;
      Approximately 11 to 24 patients in total will be enrolled in Part 1, covering 5 dose levels&#xD;
      with the primary objective of determining the safety and tolerability of OMO-103 and defining&#xD;
      an appropriate dose for further evaluation in Part 2.&#xD;
&#xD;
      The study will start with an accelerated-titration dose-escalation scheme enrolling one&#xD;
      evaluable patient per cohort for the first 2 dose levels followed by a classic 3+3 design.&#xD;
&#xD;
      • Part 2: Dose expansion where at least 3 parallel groups of patients with advanced Non Small&#xD;
      Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC) and Colorectal Cancer (CRC)&#xD;
      will be treated at the recommended Phase 2 dose (RP2D) of OMO-103 to further characterise the&#xD;
      safety, tolerability, PK, PD and anti-tumour activity of OMO-103.&#xD;
&#xD;
      Approximately 18 patients will be enrolled in each of the 3 parallel groups of patients&#xD;
      (NSCLC, TNBC, CRC) in Part 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>accelerated titration design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Number of patients with treatment related AEs according to NCI CTCAE v 5</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Objective Response Rate (ORR) according to RECIST 1.1</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Objective Response Rate (ORR) according to RECIST 1.1</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 &amp; 2: area under the curve (AUC)</measure>
    <time_frame>0, 5, 30, 60 min, 1, 2, 6, 24, 48, 76, 94 hours after end of infusion</time_frame>
    <description>Pharmacokinetics of OMO-103</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 &amp; 2: minimum concentration (Cmin)</measure>
    <time_frame>0, 5, 30, 60 min, 1, 2, 6, 24, 48, 76, 94 hours after end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 &amp; 2: maximum concentration (Cmax)</measure>
    <time_frame>0, 5, 30, 60 min, 1, 2, 6, 24, 48, 76, 94 hours after end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 &amp; 2: elimination half life (t1/2)</measure>
    <time_frame>0, 5, 30, 60 min, 1, 2, 6, 24, 48, 76, 94 hours after end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 &amp; 2: time to reach Cmax (tmax)</measure>
    <time_frame>0, 5, 30, 60 min, 1, 2, 6, 24, 48, 76, 94 hours after end of infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>NSCLC</condition>
  <condition>Triple-negative Breast Cancer</condition>
  <condition>CRC</condition>
  <arm_group>
    <arm_group_label>OMO-103</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OMO-103 will be administered intravenously as 30 min infusion once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OMO-103</intervention_name>
    <description>OMO-103 will be administered intravenously as 30 min infusion once weekly</description>
    <arm_group_label>OMO-103</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
        - Male or female patients, 18 years of age or older who sign the informed consent document,&#xD;
        are willing and able to comply with the study protocol and have:&#xD;
&#xD;
        Part 1 (Dose Escalation):&#xD;
&#xD;
        - Histologically or cytologically proven advanced solid tumour for which there is no&#xD;
        curative therapy and has progressed on Standard of Care (SOC) treatment or is intolerant to&#xD;
        or has no available SOC or SOC unacceptable.&#xD;
&#xD;
        Part 2 (Dose Expansion):&#xD;
&#xD;
        - Histologically or cytologically proven advanced NSCLC whose tumours are KRAS-mutated and&#xD;
        where the disease has progressed after a chemotherapy and immunotherapy regimen (at least&#xD;
        two prior lines of standard therapy), advanced TNBC where the disease has progressed after&#xD;
        having received anthracyclines and taxanes (at least two prior lines of standard therapy)&#xD;
        and advanced CRC whose tumours are RAS mutated and where the disease has progressed after&#xD;
        at least two prior lines of standard therapy.&#xD;
&#xD;
        Parts 1 and 2:&#xD;
&#xD;
          -  Patient must have measurable disease as per RECIST v1.1 criteria&#xD;
&#xD;
          -  Tumour biopsy (either from the primary tumour or from metastases) during Screening and&#xD;
             during Treatment should be obtained from the patients, if feasible.&#xD;
&#xD;
          -  Documented progression on or following the last line of therapy.&#xD;
&#xD;
          -  ECOG performance status up to 1.&#xD;
&#xD;
          -  Life expectancy of ≥12 weeks.&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
        Parts 1 and 2:&#xD;
&#xD;
          -  Systemic anti-cancer therapy within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Radiation therapy within 4 weeks prior to study entry. Localised palliative&#xD;
             radiotherapy to non-target lesions is allowed.&#xD;
&#xD;
          -  Non-malignant systemic disease including cerebrovascular accident (CVA), unstable&#xD;
             angina pectoris, unstable atrial fibrillation, unstable cardiac arrhythmia, myocardial&#xD;
             infarction in the last 6 months, New York Heart Association (NYHA) Class III or IV&#xD;
             heart failure, coagulation abnormalities and clinically significant pulmonary&#xD;
             compromise, particularly a requirement for supplemental oxygen use to maintain&#xD;
             adequate oxygenation in the previous 6 months.&#xD;
&#xD;
          -  Patients with a history of congenital or acquired immunodeficiency syndrome, or&#xD;
             currently receiving immunosuppressive therapy &gt;10 mg prednisolone or equivalent.&#xD;
             Patients receiving inhaled or topical corticosteroids are eligible.&#xD;
&#xD;
          -  Patients with symptomatic or unstable central nervous system (CNS) primary tumour or&#xD;
             metastases and/or carcinomatous meningitis. Patients with documented treated CNS&#xD;
             metastases stable for at least 4 weeks may be enrolled at the discretion of the&#xD;
             Investigator.&#xD;
&#xD;
          -  Patients with need of therapeutic anticoagulation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Garralda, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Vall d´Hebron; Oncology Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MANUELA NIEWEL, MD, PhD</last_name>
    <phone>+34670327414</phone>
    <email>mniewel@peptomyc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josefa Morales, PhD</last_name>
    <phone>+34654937746</phone>
    <email>pmorales@peptomyc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Garralda, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Elena Garralda, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Moreno, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Victor Moreno, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emiliano Calvo, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Emiliano Calvo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MYC-Inhibitor</keyword>
  <keyword>First in human</keyword>
  <keyword>solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

